Skip to content

Government Computer News
Government Computer News


Post Newsweek Tech

Visit our other sites
  Washington Technology
  FOSE
 Current Issue  Columnists  Products Central  Site Map  Events  Subscribe  My Account
 Search GCN
 Advanced Search
 |  Help

Hot Topics
Biometrics
Content Management
Defense IT
E-Government
Homeland Security
IT Infrastructure
Mobile & Wireless
New Products / Technology
Outsourcing
Policy / Regulation
Procurement
Section 508
Security
State & Local
Storage
Web
Work force / Training
GCN Management
Business Process (BPM)
Enterprise Architecture
Executive Center
Portfolio / Program / Project
Current Management Edition
GCN in print


Government Computer News

Subscribe

GCN Management

Tech Edition

Sponsor message
Archives


Online Resources


GCN Events/Seminars


Sponsor Forums


Technology Reports

Index of reports
HP blade servers
HP ProLiant DL145



  Printer-Friendly Version  E-Mail This Article
  Purchase A Reprint  Link To This Page

 Sponsorship Information and Announcements

 Sponsorship Information and Announcements



NIH to provide $144 million for cancer nanotechnology

By Mary Mosquera
GCN Staff


The National Institutes of Health’s National Cancer Institute announced today a $144.3 million, five-year initiative to develop and apply nanotechnology to cancer research.

Nanotechnology expands the scientific advances in genomics and proteomics and builds on scientists’ understanding of the molecular underpinnings of cancer, the agency said. NIH is part of the Health and Human Services Department.

"Nanotechnology has the potential to radically increase our options for prevention, diagnosis and treatment of cancer," said Dr. Andrew von Eschenbach, director of the National Cancer Institute.

Nanotechnology, the development and engineering of devices so small that they are measured on a molecular scale, has already demonstrated promising results in cancer research and treatment, he said. NIH plans that the initiative, the NCI Alliance for Nanotechnology in Cancer, will integrate cancer-related nanotechnology research from public and private organizations and accelerate its application into clinical practice. It will encompass partnerships involving physicists, biologists, clinicians, engineers and other experts that can translate knowledge on cancer and nanotechnology into clinically useful products.

The National Cancer Institute will work with the National Institute of Standards and Technology to collaborate on standards and with the Food and Drug Administration to define the critical pathway for nanotechnologies to reach the clinic.